Naxitamab

• Description:

  Naxitamab (Hu3F8) is a humanized monoclonal antibody targeting the disialoganglioside GD2. Naxitamab can be used in research of neuroblastoma, osteosarcoma and other GD2-positive cancers[1].

• Product Name Alternative:

  Naxitamab-gqgk; Humanized 3F8; Hu3F8

• UNSPSC:

  12352203

• Target:

  Others

• Type:

  Inhibitory Antibodies

• Related Pathways:

  Others

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/naxitamab.html

• Purity:

  99.84

• Solubility:

  10 mM in DMSO

• Smiles:

  [Naxitamab]

• Molecular Weight:

  (144.38 kDa)

• References & Citations:

  [1]Cheung NK, et, al. Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo. Oncoimmunology. 2012 Jul 1;1 (4) :477-486.|[2]Markham A. Naxitamab: First Approval. Drugs. 2021 Feb;81 (2) :291-296.

• Shipping Conditions:

  Dry Ice

• Storage Conditions:

  Store at -80°C for 2 years

• Scientific Category:

  Inhibitory Antibodies

• Clinical Information:

  Phase 4

• CAS Number:

  1879925-92-4